OrganOx Raises £25M to Advance Normothermic Machine Perfusion
OrganOx, a medical device company based in Oxford, UK, recently closed a successful funding round, raising a significant £25M in Growth funding. The round was led by Lauxera Capital Partners, a prominent investment firm. With this new capital infusion, OrganOx plans to expand its commercial footprint, construct state-of-the-art manufacturing facilities, and carry out a wide range of post-market clinical evaluations. The company's ultimate goal is to further advance the field of normothermic machine perfusion.
Established in 2008 by two esteemed Oxford University Professors, Peter Friend and Constantin Coussios, OrganOx has become a leader in the field of medical innovation.
Peter Friend, a Professor of Surgery, brings his vast expertise to the company, while Constantin Coussios, a Professor of Biomedical Engineering, contributes his extensive knowledge to the team. Under the leadership of CEO Craig Marshall, OrganOx specializes in the development and utilization of normothermic machine perfusion technology. Their groundbreaking device, called metra, utilizes proprietary NMP technology to maintain donor livers in a functional state for up to 24 hours prior to transplantation.
The metra device represents a paradigm shift in organ transplantation. It provides an automated normothermic machine perfusion solution that continuously monitors and evaluates the liver. This allows surgeons to make evidence-based decisions regarding the viability of a donor organ, enabling the testing and transplantation of organs that were previously deemed unsuitable for transplantation. The metra device has already received the CE Mark certification in Europe and has been approved for use in the United States. Since its inception, OrganOx's NMP technology has supported over 2,500 liver transplants worldwide, revolutionizing the field.
They've invested in OrganOx
Get to know these Healthtech investors
Click here for a full list of 6,481+ startup investors in the UK